Stoke Therapeutics, Inc.
STOK · FY2025 · Fiscal year ended Dec 31, 2025 · 10-K filed Mar 2026
Open the dashboardInfographicSummary
FY2025 key figures
| $ | FY2025 | FY2024 | Change |
|---|---|---|---|
| Revenue | $184M | $36.5M | +405% |
| Operating income | −$20.6M | −$101M | +79.7% |
| Net income | −$6.88M | −$89.0M | +92.3% |
Latest quarter: Q3 2026
Form 10-Q · Three months ended Sep 30, 2026 · filed Nov 3, 2026
| $ | Q3 2026 | Year earlier | Change |
|---|---|---|---|
| Revenue | $11.3M | $10.6M | +6.6% |
| Operating income | −$77.3M | −$43.1M | −79.4% |
| Net income | −$73.6M | −$38.3M | −92.2% |
Q3 2026 dashboardQ3 2026 infographic
Questions
- What was Stoke Therapeutics's revenue in FY2025?
- $184M in FY2025 (Fiscal year ended Dec 31, 2025), +405% vs $36.5M a year earlier, per its 10-K filed Mar 2026.
- Was Stoke Therapeutics profitable in FY2025?
- No: net income was −$6.88M and operating income −$20.6M in FY2025.
- What was Stoke Therapeutics's revenue in Q3 2026?
- $11.3M (+6.6% vs a year earlier), per its Form 10-Q filed Nov 3, 2026.